Disc Medicine, Inc.

Disc Medicine, Inc. (Nasdaq: GMTX) filed a Form 10-Q quarterly report with the U.S. Securities and Exchange Commission on November 12, 2020, bearing accession number 0001213900-20-036232. The company operates in the biotechnology sector with a focus on hematology and rare blood diseases, developing therapeutic candidates targeting disorders of red blood cell production. The 10-Q provides a disclosure of the company's financial condition, results of operations, and business developments for the applicable quarterly period. SpacDesk tracks SEC filings, corporate disclosures, and SPAC-related transactions across the life sciences and healthcare universe. Sign up for full filing data, financial metrics, and deal history on SpacDesk to follow GMTX and the broader biotech landscape.